Loading…
Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study
We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration. The major eligibility criteria included patients with lung cancer...
Saved in:
Published in: | Japanese journal of clinical oncology 2013-11, Vol.43 (11), p.1105-1109 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203 |
---|---|
cites | cdi_FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203 |
container_end_page | 1109 |
container_issue | 11 |
container_start_page | 1105 |
container_title | Japanese journal of clinical oncology |
container_volume | 43 |
creator | Horinouchi, Hidehito Kubota, Kaoru Itani, Hidetoshi Taniyama, Tomoko Katsui Nakamichi, Shinji Wakui, Hiroshi Kanda, Shintaro Nokihara, Hiroshi Yamamoto, Noboru Sekine, Ikuo Tamura, Tomohide |
description | We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration.
The major eligibility criteria included patients with lung cancer for whom a ≥75 mg/m(2) cisplatin-based regimen was indicated and adequate organ function. Cisplatin was administered with pre- and post-hydration containing 10 mEq of potassium chloride in 500 ml of fluid over a 60-min period. Immediately before the administration of cisplatin, mannitol (20%, 200 ml) was administered as forced diuresis over 30 min. And magnesium sulfate (8 mEq) was added to pre-hydration.
Forty-four patients were enrolled between April and December 2011. The patients included 29 men and 15 women with a median (range) age of 64 (42-74) years. Twenty patients received cisplatin and pemetrexed as their most frequent regimen and 38 patients received three to four cycles of chemotherapy. The median (range) duration and volume of the chemotherapies were 4.0 (3.3-6.8) h and 1600 (1550-2050) ml, respectively. Of the 44 patients, 43 (97.8%) completed the cisplatin-based chemotherapy without Grade 2 or higher renal dysfunction. The only patient who had Grade 2 elevation in creatinine (maximum value 1.7 mg/dl) had prompt improvement in creatinine levels and completed four cycles of chemotherapy.
The short hydration is safe without severe renal toxicities in regimens containing cisplatin (≥75 mg/m(2)) for patients with lung cancer. |
doi_str_mv | 10.1093/jjco/hyt122 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1449281233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1449281233</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203</originalsourceid><addsrcrecordid>eNo9kN1KwzAAhYMobk6vvJdcTqQuP22TeifDPxh4oV6XNE3WjDatSar0EXwQX8wnsWPTqwOHj8PhA-Aco2uMMrrYbGS7qIaACTkAUxynSURTgg_BFNGUR4RjPAEn3m8QQgmP2TGYkBihNEHJFPQvVesCrIbSiWBaC42FslJNGyrlRDdA2dogjDV2DaXxXT1SFs5_vr5ZApv1oiGXULcOdmOvbPDw04QK1v0WF1YqdwMF7FzrOyWD-VDQh74cTsGRFrVXZ_ucgbf7u9flY7R6fnha3q4iSRMUIl0yzjjBnBFNuWICYaULpAWmXMQqkzErJKOpZAnJuKaM4lLrNOaEFawkiM7AfLc7PnjvlQ95Y7xUdS2sanuf4zjORj-E0hG92qFyPOud0nnnTCPckGOUbz3nW8_5zvNIX-yH-6JR5T_7J5b-Aut2e_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449281233</pqid></control><display><type>article</type><title>Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study</title><source>Oxford Journals Online</source><creator>Horinouchi, Hidehito ; Kubota, Kaoru ; Itani, Hidetoshi ; Taniyama, Tomoko Katsui ; Nakamichi, Shinji ; Wakui, Hiroshi ; Kanda, Shintaro ; Nokihara, Hiroshi ; Yamamoto, Noboru ; Sekine, Ikuo ; Tamura, Tomohide</creator><creatorcontrib>Horinouchi, Hidehito ; Kubota, Kaoru ; Itani, Hidetoshi ; Taniyama, Tomoko Katsui ; Nakamichi, Shinji ; Wakui, Hiroshi ; Kanda, Shintaro ; Nokihara, Hiroshi ; Yamamoto, Noboru ; Sekine, Ikuo ; Tamura, Tomohide</creatorcontrib><description>We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration.
The major eligibility criteria included patients with lung cancer for whom a ≥75 mg/m(2) cisplatin-based regimen was indicated and adequate organ function. Cisplatin was administered with pre- and post-hydration containing 10 mEq of potassium chloride in 500 ml of fluid over a 60-min period. Immediately before the administration of cisplatin, mannitol (20%, 200 ml) was administered as forced diuresis over 30 min. And magnesium sulfate (8 mEq) was added to pre-hydration.
Forty-four patients were enrolled between April and December 2011. The patients included 29 men and 15 women with a median (range) age of 64 (42-74) years. Twenty patients received cisplatin and pemetrexed as their most frequent regimen and 38 patients received three to four cycles of chemotherapy. The median (range) duration and volume of the chemotherapies were 4.0 (3.3-6.8) h and 1600 (1550-2050) ml, respectively. Of the 44 patients, 43 (97.8%) completed the cisplatin-based chemotherapy without Grade 2 or higher renal dysfunction. The only patient who had Grade 2 elevation in creatinine (maximum value 1.7 mg/dl) had prompt improvement in creatinine levels and completed four cycles of chemotherapy.
The short hydration is safe without severe renal toxicities in regimens containing cisplatin (≥75 mg/m(2)) for patients with lung cancer.</description><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyt122</identifier><identifier>PMID: 24006505</identifier><language>eng</language><publisher>England</publisher><subject><![CDATA[Adenocarcinoma - drug therapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers - blood ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Squamous Cell - drug therapy ; Chemotherapy, Adjuvant ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Creatinine - blood ; Female ; Fluid Therapy - methods ; Gastrointestinal Tract - drug effects ; Glutamates - administration & dosage ; Glutamates - adverse effects ; Guanine - administration & dosage ; Guanine - adverse effects ; Guanine - analogs & derivatives ; Humans ; Japan ; Kidney - drug effects ; Kidney - metabolism ; Kidney - physiopathology ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Lung Neoplasms - surgery ; Magnesium - administration & dosage ; Male ; Middle Aged ; Pemetrexed ; Prospective Studies ; Radiotherapy, Adjuvant ; Renal Insufficiency - chemically induced ; Renal Insufficiency - prevention & control ; Treatment Outcome]]></subject><ispartof>Japanese journal of clinical oncology, 2013-11, Vol.43 (11), p.1105-1109</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203</citedby><cites>FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24006505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horinouchi, Hidehito</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Itani, Hidetoshi</creatorcontrib><creatorcontrib>Taniyama, Tomoko Katsui</creatorcontrib><creatorcontrib>Nakamichi, Shinji</creatorcontrib><creatorcontrib>Wakui, Hiroshi</creatorcontrib><creatorcontrib>Kanda, Shintaro</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><creatorcontrib>Sekine, Ikuo</creatorcontrib><creatorcontrib>Tamura, Tomohide</creatorcontrib><title>Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration.
The major eligibility criteria included patients with lung cancer for whom a ≥75 mg/m(2) cisplatin-based regimen was indicated and adequate organ function. Cisplatin was administered with pre- and post-hydration containing 10 mEq of potassium chloride in 500 ml of fluid over a 60-min period. Immediately before the administration of cisplatin, mannitol (20%, 200 ml) was administered as forced diuresis over 30 min. And magnesium sulfate (8 mEq) was added to pre-hydration.
Forty-four patients were enrolled between April and December 2011. The patients included 29 men and 15 women with a median (range) age of 64 (42-74) years. Twenty patients received cisplatin and pemetrexed as their most frequent regimen and 38 patients received three to four cycles of chemotherapy. The median (range) duration and volume of the chemotherapies were 4.0 (3.3-6.8) h and 1600 (1550-2050) ml, respectively. Of the 44 patients, 43 (97.8%) completed the cisplatin-based chemotherapy without Grade 2 or higher renal dysfunction. The only patient who had Grade 2 elevation in creatinine (maximum value 1.7 mg/dl) had prompt improvement in creatinine levels and completed four cycles of chemotherapy.
The short hydration is safe without severe renal toxicities in regimens containing cisplatin (≥75 mg/m(2)) for patients with lung cancer.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Creatinine - blood</subject><subject>Female</subject><subject>Fluid Therapy - methods</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Glutamates - administration & dosage</subject><subject>Glutamates - adverse effects</subject><subject>Guanine - administration & dosage</subject><subject>Guanine - adverse effects</subject><subject>Guanine - analogs & derivatives</subject><subject>Humans</subject><subject>Japan</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Kidney - physiopathology</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lung Neoplasms - surgery</subject><subject>Magnesium - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pemetrexed</subject><subject>Prospective Studies</subject><subject>Radiotherapy, Adjuvant</subject><subject>Renal Insufficiency - chemically induced</subject><subject>Renal Insufficiency - prevention & control</subject><subject>Treatment Outcome</subject><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNo9kN1KwzAAhYMobk6vvJdcTqQuP22TeifDPxh4oV6XNE3WjDatSar0EXwQX8wnsWPTqwOHj8PhA-Aco2uMMrrYbGS7qIaACTkAUxynSURTgg_BFNGUR4RjPAEn3m8QQgmP2TGYkBihNEHJFPQvVesCrIbSiWBaC42FslJNGyrlRDdA2dogjDV2DaXxXT1SFs5_vr5ZApv1oiGXULcOdmOvbPDw04QK1v0WF1YqdwMF7FzrOyWD-VDQh74cTsGRFrVXZ_ucgbf7u9flY7R6fnha3q4iSRMUIl0yzjjBnBFNuWICYaULpAWmXMQqkzErJKOpZAnJuKaM4lLrNOaEFawkiM7AfLc7PnjvlQ95Y7xUdS2sanuf4zjORj-E0hG92qFyPOud0nnnTCPckGOUbz3nW8_5zvNIX-yH-6JR5T_7J5b-Aut2e_g</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Horinouchi, Hidehito</creator><creator>Kubota, Kaoru</creator><creator>Itani, Hidetoshi</creator><creator>Taniyama, Tomoko Katsui</creator><creator>Nakamichi, Shinji</creator><creator>Wakui, Hiroshi</creator><creator>Kanda, Shintaro</creator><creator>Nokihara, Hiroshi</creator><creator>Yamamoto, Noboru</creator><creator>Sekine, Ikuo</creator><creator>Tamura, Tomohide</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201311</creationdate><title>Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study</title><author>Horinouchi, Hidehito ; Kubota, Kaoru ; Itani, Hidetoshi ; Taniyama, Tomoko Katsui ; Nakamichi, Shinji ; Wakui, Hiroshi ; Kanda, Shintaro ; Nokihara, Hiroshi ; Yamamoto, Noboru ; Sekine, Ikuo ; Tamura, Tomohide</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Creatinine - blood</topic><topic>Female</topic><topic>Fluid Therapy - methods</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Glutamates - administration & dosage</topic><topic>Glutamates - adverse effects</topic><topic>Guanine - administration & dosage</topic><topic>Guanine - adverse effects</topic><topic>Guanine - analogs & derivatives</topic><topic>Humans</topic><topic>Japan</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Kidney - physiopathology</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lung Neoplasms - surgery</topic><topic>Magnesium - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pemetrexed</topic><topic>Prospective Studies</topic><topic>Radiotherapy, Adjuvant</topic><topic>Renal Insufficiency - chemically induced</topic><topic>Renal Insufficiency - prevention & control</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horinouchi, Hidehito</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Itani, Hidetoshi</creatorcontrib><creatorcontrib>Taniyama, Tomoko Katsui</creatorcontrib><creatorcontrib>Nakamichi, Shinji</creatorcontrib><creatorcontrib>Wakui, Hiroshi</creatorcontrib><creatorcontrib>Kanda, Shintaro</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><creatorcontrib>Sekine, Ikuo</creatorcontrib><creatorcontrib>Tamura, Tomohide</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horinouchi, Hidehito</au><au>Kubota, Kaoru</au><au>Itani, Hidetoshi</au><au>Taniyama, Tomoko Katsui</au><au>Nakamichi, Shinji</au><au>Wakui, Hiroshi</au><au>Kanda, Shintaro</au><au>Nokihara, Hiroshi</au><au>Yamamoto, Noboru</au><au>Sekine, Ikuo</au><au>Tamura, Tomohide</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2013-11</date><risdate>2013</risdate><volume>43</volume><issue>11</issue><spage>1105</spage><epage>1109</epage><pages>1105-1109</pages><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration.
The major eligibility criteria included patients with lung cancer for whom a ≥75 mg/m(2) cisplatin-based regimen was indicated and adequate organ function. Cisplatin was administered with pre- and post-hydration containing 10 mEq of potassium chloride in 500 ml of fluid over a 60-min period. Immediately before the administration of cisplatin, mannitol (20%, 200 ml) was administered as forced diuresis over 30 min. And magnesium sulfate (8 mEq) was added to pre-hydration.
Forty-four patients were enrolled between April and December 2011. The patients included 29 men and 15 women with a median (range) age of 64 (42-74) years. Twenty patients received cisplatin and pemetrexed as their most frequent regimen and 38 patients received three to four cycles of chemotherapy. The median (range) duration and volume of the chemotherapies were 4.0 (3.3-6.8) h and 1600 (1550-2050) ml, respectively. Of the 44 patients, 43 (97.8%) completed the cisplatin-based chemotherapy without Grade 2 or higher renal dysfunction. The only patient who had Grade 2 elevation in creatinine (maximum value 1.7 mg/dl) had prompt improvement in creatinine levels and completed four cycles of chemotherapy.
The short hydration is safe without severe renal toxicities in regimens containing cisplatin (≥75 mg/m(2)) for patients with lung cancer.</abstract><cop>England</cop><pmid>24006505</pmid><doi>10.1093/jjco/hyt122</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0368-2811 |
ispartof | Japanese journal of clinical oncology, 2013-11, Vol.43 (11), p.1105-1109 |
issn | 0368-2811 1465-3621 |
language | eng |
recordid | cdi_proquest_miscellaneous_1449281233 |
source | Oxford Journals Online |
subjects | Adenocarcinoma - drug therapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers - blood Carcinoma, Small Cell - drug therapy Carcinoma, Squamous Cell - drug therapy Chemotherapy, Adjuvant Cisplatin - administration & dosage Cisplatin - adverse effects Creatinine - blood Female Fluid Therapy - methods Gastrointestinal Tract - drug effects Glutamates - administration & dosage Glutamates - adverse effects Guanine - administration & dosage Guanine - adverse effects Guanine - analogs & derivatives Humans Japan Kidney - drug effects Kidney - metabolism Kidney - physiopathology Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Lung Neoplasms - surgery Magnesium - administration & dosage Male Middle Aged Pemetrexed Prospective Studies Radiotherapy, Adjuvant Renal Insufficiency - chemically induced Renal Insufficiency - prevention & control Treatment Outcome |
title | Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A08%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20hydration%20in%20chemotherapy%20containing%20cisplatin%20(%E2%89%A575%20mg/m2)%20for%20patients%20with%20lung%20cancer:%20a%20prospective%20study&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Horinouchi,%20Hidehito&rft.date=2013-11&rft.volume=43&rft.issue=11&rft.spage=1105&rft.epage=1109&rft.pages=1105-1109&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyt122&rft_dat=%3Cproquest_cross%3E1449281233%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-fd787821872f38e7a01efb0fa138a4e9c47bc736c75298f3731dff64827b7d203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1449281233&rft_id=info:pmid/24006505&rfr_iscdi=true |